Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials

Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials

Purpose: Sorafenib is recommended for patients with hepatocellular carcinoma refractory to transarterial chemoembolization but with unsatisfactory overall survival and tumor response rate. Previously published studies showed hepatic arterial infusion chemotherapy of oxaliplatin, fluorouracil, and le...

Full description

Bibliographic Details
Main Authors: YeXing Huang MD, LiHong Zhang MD, MinKe He MD, ZhiCheng Lai MD, XiaoYun Bu MD, DongSheng Wen MD, QiJiong Li MD, Li Xu MD, Wei Wei MD, YaoJun Zhang MD, ZhongGuo Zhou MD, MinShan Chen MD, RongPing Guo MD, Ming Shi MD, Anna Kan MD
Format: Article
Language:English
Published: SAGE Publishing 2022-12-01
Series:Technology in Cancer Research & Treatment
Online Access:https://doi.org/10.1177/15330338221117389

Internet

https://doi.org/10.1177/15330338221117389

Similar Items